Patents by Inventor Martin Lenter

Martin Lenter has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9211330
    Abstract: The invention relates to biparatopic A-beta binding polypeptides and, more specifically, to biparatopic A-beta binding polypeptides comprising at least two immunoglobulin single variable domains binding to different epitopes of A-beta. The invention also relates to specific sequences of such polypeptides, methods of their production, and methods of using them, including methods of treatment of diseases such as Alzheimer's Disease.
    Type: Grant
    Filed: August 29, 2013
    Date of Patent: December 15, 2015
    Assignee: Ablynx N.V.
    Inventors: John E. Park, Cornelia Dorner-Ciossek, Stefan Hoerer, Lothar Kussmaul, Martin Lenter, Katharina Zimmerman, Gerald Beste, Toon Laeremans, Pascal Gerard Merchiers, Jo Vercammen
  • Publication number: 20140030275
    Abstract: The invention relates to biparatopic A-beta binding polypeptides and, more specifically, to biparatopic A-beta binding polypeptides comprising at least two immunoglobulin single variable domains binding to different epitopes of A-beta. The invention also relates to specific sequences of such polypeptides, methods of their production, and methods of using them, including methods of treatment of diseases such as Alzheimer's Disease.
    Type: Application
    Filed: August 29, 2013
    Publication date: January 30, 2014
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: John E. PARK, Cornelia DORNER-CIOSSEK, Stefan HOERER, Lothar KUSSMAUL, Martin LENTER, Katharina ZIMMERMANN, Gerald BESTE, Toon LAEREMANS, Pascal MERCHIERS, Jo VERCAMMEN
  • Patent number: 8618132
    Abstract: The present invention relates to alkyne compounds of general formula I wherein the groups and residues A, B, W, X, Y, Z, R1 and R2 have the meanings given in claim 1. The invention further relates to pharmaceutical compositions containing at least one alkyne according to the invention. In view of their MCH-receptor antagonistic activity the pharmaceutical compositions according to the invention are suitable for the treatment of metabolic disorders and/or eating disorders, particularly obesity, bulimia, anorexia, hyperphagia and diabetes.
    Type: Grant
    Filed: May 15, 2008
    Date of Patent: December 31, 2013
    Assignee: Boehringer Ingelheim Pharma GmbH & Co. KG
    Inventors: Dirk Stenkamp, Stephan Georg Mueller, Gerald Juergen Roth, Thorsten Lehmann-Lintz, Klaus Rudolf, Philipp Lustenberger, Kristen Arndt, Ralf R. H. Lotz, Martin Lenter
  • Patent number: 8614308
    Abstract: The invention relates to biparatopic A-beta binding polypeptides and, more specifically, to biparatopic A-beta binding polypeptides comprising at least two immunoglobulin single variable domains binding to different epitopes of A-beta. The invention also relates to specific sequences of such polypeptides, methods of their production, and methods of using them, including methods of treatment of diseases such as Alzheimer's Disease.
    Type: Grant
    Filed: September 14, 2012
    Date of Patent: December 24, 2013
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: John E. Park, Cornelia Dorner-Ciossek, Stefan Hoerer, Lothar Kussmaul, Martin Lenter, Katharina Zimmermann, Gerald Beste, Toon Laeremans, Pascal Merchiers, Jo Vercammen
  • Publication number: 20130295666
    Abstract: The present invention pertains to crystals of glucokinase regulatory protein (GKRP) and of GKRP variants, to the molecular biology of certain GKRP variants, to processes for the crystallization of GKRP and GKRP variants, to such crystals and corresponding structural information obtained by X-ray crystallography. Such crystals and crystallographic data can be used for the identification of compounds that bind to GKRP, especially of compounds that inhibit GKRP or interfere with the interaction of GKRP with its natural interacting partner Glucokinase (GK).
    Type: Application
    Filed: December 17, 2012
    Publication date: November 7, 2013
    Applicant: Boehringer Ingelheim International GmbH
    Inventors: Gisela SCHNAPP, Adina Berg, Stefan Kauschke, Martin Lenter, Alexander Pautsch, Wolfgang Rist
  • Patent number: 8420630
    Abstract: The present invention relates to trisubstituted pyrimidines of formula (I) wherein 0Ra to Re are defined as in claim 1, which are suitable for the treatment of illnesses characterized by excessive or abnormal cell proliferation, the use thereof for preparing a pharmaceutical composition with the abovementioned properties, and processes for the preparation thereof.
    Type: Grant
    Filed: February 24, 2010
    Date of Patent: April 16, 2013
    Assignees: Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals, Inc.
    Inventors: Georg Dahmann, Frank Himmelsbach, Bernd Krist, Martin Lenter, Alexander Pautsch, Gisela Schnapp, Martin Steegmaier, Helmut Wittneben, Anthony S. Prokopowicz, Walter Spevak, Andreas Schoop, Steffen Steurer
  • Publication number: 20130017209
    Abstract: The invention relates to biparatopic A-beta binding polypeptides and, more specifically, to biparatopic A-beta binding polypeptides comprising at least two immunoglobulin single variable domains binding to different epitopes of A-beta. The invention also relates to specific sequences of such polypeptides, methods of their production, and methods of using them, including methods of treatment of diseases such as Alzheimer's Disease.
    Type: Application
    Filed: September 14, 2012
    Publication date: January 17, 2013
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: John E. PARK, Cornelia DORNER-CIOSSEK, Stefan HOERER, Lothar KUSSMAUL, Martin LENTER, Katharina ZIMMERMANN, Gerald BESTE, Toon LAEREMANS, Pascal MERCHIERS, Jo VERCAMMEN
  • Patent number: 8337845
    Abstract: The invention relates to biparatopic A-beta binding polypeptides and, more specifically, to biparatopic A-beta binding polypeptides comprising at least two immunoglobulin single variable domains binding to different epitopes of A-beta. The invention also relates to specific sequences of such polypeptides, methods of their production, and methods of using them, including methods of treatment of diseases such as Alzheimer's Disease.
    Type: Grant
    Filed: March 2, 2011
    Date of Patent: December 25, 2012
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: John E. Park, Cornelia Dorner-Ciossek, Stefan Hoerer, Lothar Kussmaul, Martin Lenter, Katharina Zimmermann, Gerald Beste, Toon Laeremans, Pascal Merchiers, Jo Vercammen
  • Publication number: 20120058118
    Abstract: The invention relates to biparatopic A-beta binding polypeptides and, more specifically, to biparatopic A-beta binding polypeptides comprising at least two immunoglobulin single variable domains binding to different epitopes of A-beta. The invention also relates to specific sequences of such polypeptides, methods of their production, and methods of using them, including methods of treatment of diseases such as Alzheimer's Disease.
    Type: Application
    Filed: March 2, 2011
    Publication date: March 8, 2012
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: John E. PARK, Cornelia DORNER-CIOSSEK, Stefan HOERER, Lothar KUSSMAUL, Martin LENTER, Katharina ZIMMERMANN, Gerald BESTE, Toon LAEREMANS, Pascal MERCHIERS, Jo VERCAMMEN
  • Publication number: 20100152167
    Abstract: The present invention relates to trisubstituted pyrimidines of formula (I) wherein 0Ra to Re are defined as in claim 1, which are suitable for the treatment of illnesses characterised by excessive or abnormal cell proliferation, the use thereof for preparing a pharmaceutical composition with the abovementioned properties, and processes for the preparation thereof.
    Type: Application
    Filed: February 24, 2010
    Publication date: June 17, 2010
    Applicants: BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG, BOEHRINGER INGELHEIM PHARMACEUTICALS, INC.
    Inventors: Georg DAHMANN, Frank HIMMELSBACH, Bernd KRIST, Martin LENTER, Alexander PAUTSCH, Gisela SCHNAPP, Martin STEEGMAIER, Helmut WITTNEBEN, Anthony S. PROKOPOWICZ, Walter SPEVAK, Andreas SCHOOP, Steffen STEURER
  • Patent number: 7709480
    Abstract: The present invention relates to trisubstituted pyrimidines of formula (I) wherein 0Ra to Re are defined as in claim 1, which are suitable for the treatment of illnesses characterized by excessive or abnormal cell proliferation, the use thereof for preparing a pharmaceutical composition with the abovementioned properties, and processes for the preparation thereof.
    Type: Grant
    Filed: December 21, 2005
    Date of Patent: May 4, 2010
    Assignees: Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals, Inc.
    Inventors: Georg Dahmann, Frank Himmelsbach, Bernd Krist, Martin Lenter, Alexander Pautsch, Gisela Schapp, Martin Steegmaier, Helmut Wittneben, Anthony S. Prokopowicz, Walter Spevak, Andreas Schoop, Steffen Steurer
  • Publication number: 20090069282
    Abstract: The present invention relates to alkyne compounds of general formula I wherein the groups and residues A, B, W, X, Y, Z, R1 and R2 have the meanings given in claim 1. The invention further relates to pharmaceutical compositions containing at least one alkyne according to the invention. In view of their MCH-receptor antagonistic activity the pharmaceutical compositions according to the invention are suitable for the treatment of metabolic disorders and/or eating disorders, particularly obesity, bulimia, anorexia, hyperphagia and diabetes.
    Type: Application
    Filed: May 15, 2008
    Publication date: March 12, 2009
    Applicant: Boehringer Ingelheim Pharma GmbH & Co. KG
    Inventors: Dirk Stenkamp, Stephan Georg Mueller, Gerald Juergen Roth, Thorsten Lehmann-Lintz, Klaus Rudolf, Philipp Lustenberger, Kirsten Arndt, Ralf R. H. Lotz, Martin Lenter
  • Patent number: 7452911
    Abstract: The present invention relates to alkyne compounds of general formula I wherein the groups and residues A, B, W, X, Y, Z, R1 and R2 have the meanings given in claim 1. The invention further relates to pharmaceutical compositions containing at least one alkyne according to the invention. In view of their MCH-receptor antagonistic activity the pharmaceutical compositions according to the invention are suitable for the treatment of metabolic disorders and/or eating disorders, particularly obesity, bulimia, anorexia, hyperphagia and diabetes.
    Type: Grant
    Filed: October 30, 2003
    Date of Patent: November 18, 2008
    Assignee: Boehringer Ingelheim Pharma GmbH & Co. KG
    Inventors: Dirk Stenkamp, Stephan Georg Mueller, Gerald Juergen Roth, Thorsten Lehmann-Lintz, Klaus Rudolf, Philip Lustenberger, Kirsten Arndt, Ralf R. H. Lotz, Martin Lenter
  • Patent number: 7351719
    Abstract: The present invention relates to amide compounds of general formula I wherein the groups and residues A, B, b, W, X, Y, Z, R1, R2 and R3 have the meanings given in claim 1. Moreover the invention relates to pharmaceutical compositions containing at least one amide according to the invention. In view of the MCH receptor-antagonistic activity the pharmaceutical compositions according to the invention are suitable for the treatment of metabolic disorders and/or eating disorders, particularly obesity, bulimia, anorexia, hyperphagia and diabetes.
    Type: Grant
    Filed: October 31, 2003
    Date of Patent: April 1, 2008
    Assignee: Boehringer Ingelheim Pharma GmbH & Co. KG
    Inventors: Dirk Stenkamp, Stephan Georg Mueller, Gerald Juergen Roth, Philipp Lustenberger, Klaus Rudolf, Thorsten Lehmann-Lintz, Kirsten Arndt, Ralf Lotz, Martin Lenter, Heike-Andrea Wieland
  • Patent number: 7173028
    Abstract: The present invention relates to trisubstituted pyrimidines of formula (I) wherein 0Ra to Re are defined as in claim 1, which are suitable for the treatment of illnesses characterised by excessive or abnormal cell proliferation, the use thereof for preparing a pharmaceutical composition with the abovementioned properties, and processes for the preparation thereof.
    Type: Grant
    Filed: October 16, 2002
    Date of Patent: February 6, 2007
    Assignees: Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals, Inc.
    Inventors: Georg Dahmann, Frank Himmelsbach, Bernd Krist, Martin Lenter, Alexander Pautsch, Gisela Schnapp, Martin Steegmaier, Helmut Wittneben, Anthony S. Prokopowicz, Walter Spevak, Andreas Schoop, Steffen Steurer
  • Patent number: 7166615
    Abstract: Indolinones of general formula I which are inhibitors of cell proliferation, particularly of tumor cells, and inhibitors of protein kinases.
    Type: Grant
    Filed: August 22, 2003
    Date of Patent: January 23, 2007
    Assignee: Boehringer Ingelheim Pharma GmbH & Co. KG
    Inventors: Rainer Walter, Armin Heckel, Gerald Roth, Joerg Kley, Gisela Schnapp, Martin Lenter, Jacobus Van Meel, Walter Spevak, Ulrike Weyer-Czernilofsky
  • Patent number: 7160901
    Abstract: Indolinones of general formula I which are inhibitors of cell proliferation, particularly of tumor cells, and inhibitors of protein kinases.
    Type: Grant
    Filed: August 22, 2003
    Date of Patent: January 9, 2007
    Assignee: Boehringer Ingelheim Pharma GmbH & Co. KG
    Inventors: Rainer Walter, Armin Heckel, Gerald Roth, Joerg Kley, Gisela Schnapp, Martin Lenter, Jacobus Van Meel, Walter Spevak, Ulrike Weyer-Czernilofsky
  • Publication number: 20060100211
    Abstract: The present invention relates to trisubstituted pyrimidines of formula (I) wherein 0Ra to Re are defined as in claim 1, which are suitable for the treatment of illnesses characterised by excessive or abnormal cell proliferation, the use thereof for preparing a pharmaceutical composition with the abovementioned properties, and processes for the preparation thereof.
    Type: Application
    Filed: December 21, 2005
    Publication date: May 11, 2006
    Applicant: Boehringer Ingelheim Pharma GmbH & Co. KG
    Inventors: Georg Dahmann, Frank Himmelsbach, Bernd Krist, Martin Lenter, Alexander Pautsch, Gisela Schnapp, Martin Steegmaier, Helmut Wittneben, Anthony Prokopowicz, Walter Spevak, Andreas Schoop, Steffen Steurer
  • Publication number: 20050148507
    Abstract: The invention relates to a process for preparing pyroGlu-MCP-1 from recombinantly produced Gln-MCP-1, wherein Gln-MCP-1 is incubated at a temperature in the range from 30° C. and 80° C. in a buffer solution with a salt concentration in the range from 10 mM to 160 mM and a pH in the range from 2 to 7.5, until at least 90% of the MCP-1 is present in the form of the pyroGlu-MCP-1.
    Type: Application
    Filed: April 28, 2004
    Publication date: July 7, 2005
    Applicant: Boehringer Ingelheim International GmbH
    Inventors: Robert Wandl, Roman Necina, Henri Doods, Martin Lenter, Randolph Seidler
  • Publication number: 20040242572
    Abstract: The present invention relates to carboxamide compounds of general formula I 1
    Type: Application
    Filed: August 22, 2003
    Publication date: December 2, 2004
    Applicant: Boehringer Ingelheim International GmbH
    Inventors: Dirk Stenkamp, Martin Lenter, Heike-Andrea Wieland, Klaus Rudolf, Stephan George Mueller, Ralf R.H. Lotz, Kirsten Arndt, Philipp Lustenberger, Thorsten Lehmann-Lintz